Clinical Trial: Terazosin And Metabolic Engagement in Alzheimer's Disease

U.S., Sept. 2 -- ClinicalTrials.gov registry received information related to the study (NCT07796308) titled 'Terazosin And Metabolic Engagement in Alzheimer's Disease' on Aug. 27.

Brief Summary: The TAME-AD trial will be a randomized, double-blind, placebo-controlled Phase IIa clinical trial to evaluate the metabolic target engagement of terazosin for the treatment of Alzheimer's disease.

Study Start Date: Aug. 01, 2027

Study Type: INTERVENTIONAL

Condition: Alzheimer s Disease

Intervention: DRUG: Terazosin (Hytrin)

In this double blind, randomized, placebo controlled phase IIa clinical trial, subjects randomized into the Terazosin group will receive Terazosin hydrochloride treatment for 78 weeks. Participants will start at 1mg daily...